ArticleExperimental cell research2004
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Article in Experimental cell research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 54 citations in OpenAlex.
- Biophysical phenotype mixtures reveal advantages for tumor muscle invasion in vivo.Biophysical journal · 2023Article
- Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer.Journal of clinical medicine · 2023Article
- Loss of α6β4 Integrin-Mediated Hemidesmosomes Promotes Prostate Epithelial Cell Migration by Stimulating Focal Adhesion Dynamics.Frontiers in cell and developmental biology · 2022Article
- DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma.Scientific reports · 2021Article
- Article
- Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer.Cancer research · 2019Article
- Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.American journal of clinical and experimental urology · 2019Article
- α6-Integrin alternative splicing: distinct cytoplasmic variants in stem cell fate specification and niche interaction.Stem cell research & therapy · 2018Review
- Schwann Cells Increase Prostate and Pancreatic Tumor Cell Invasion Using Laminin Binding A6 Integrin.Journal of cellular biochemistry · 2016Article
- Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers.American journal of translational research · 2016Article
- Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.Clinical & experimental metastasis · 2015Article
- Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.Biochemical and biophysical research communications · 2014Article
- High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures.Cancer medicine · 2014Article
- Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model.Molecular cancer therapeutics · 2014Article
- The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Frontiers in oncology · 2014Review
- A high level of integrin α6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype.Digestive diseases and sciences · 2013Article
- Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.Clinical & experimental metastasis · 2013Article
- Characteristic features of stem cells in glioblastomas: from cellular biology to genetics.Brain pathology (Zurich, Switzerland) · 2012Review
- Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.Molecular cancer research : MCR · 2011Article
- Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils.American journal of respiratory and critical care medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
During human prostate cancer progression, the integrin alpha6beta1 (laminin receptor) is expressed on the cancer cell surface during invasion and in lymph node metastases. We previously identified a novel structural variant of the alpha6 integrin called alpha6p. This variant was produced on the cell surface and was missing the beta-barrel extracellular domain. Using several different concentrations of amiloride, aminobenzamidine and PAI-1 and the urokinase-type plasminogen activator (uPA) function-blocking antibody (3689), we showed that uPA, acting as a protease, is responsible for production of alpha6p. We also showed that addition of uPA in the culture media of cells that do not produce alpha6p, resulted in a dose-dependent alpha6p production. In contrast, the addition of uPA did not result in the cleavage of other integrins. Using alpha2-antiplasmin and plasmin depleted media, we observed that uPA cleaves the alpha6 integrin directly. Further, 12-o-tetradecanoyl-phorbol-13-acetate (TPA) induced the production of alpha6p, and this induction was abolished by PAI-1 but not alpha2-antiplasmin. Finally, the alpha6p integrin variant was detected in invasive human prostate carcinoma tissue indicating that this is not a tissue culture phenomenon. These data, taken together, suggest that this is a novel function of uPA, that is, to remove the beta-barrel ligand-binding domain of the integrin while preserving its heterodimer association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.